(Q30300308)

15 June 2017

1 reference

title

Uterine carcinosarcoma: A review of the literature (English)

1 reference

15 June 2017

uterine carcinosarcoma

1 reference

Leigh A Cantrell

1

1 reference

15 June 2017

Stephanie V Blank

series ordinal

2

1 reference

15 June 2017

Linda R Duska

series ordinal

3

1 reference

15 June 2017

language of work or name

English

0 references

publication date

21 March 2015

1 reference

15 June 2017

1 reference

15 June 2017

137

1 reference

15 June 2017

3

1 reference

15 June 2017

581-588

1 reference

15 June 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Uterine carcinosarcomas: incidence and trends in management and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Uterine carcinosarcoma is derived from a single stem cell: an in vitro study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Patterns of recurrence in malignant mixed müllerian tumor of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Female genital tract cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Black race independently predicts worse survival in uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Uterine carcinosarcoma in association with tamoxifen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Uterine carcinosarcoma associated with hereditary nonpolyposis colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Molecular and pathologic aspects of endometrial carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Bifunctional pathway of uterine carcinosarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Rare uterine cancer: carcinosarcomas. Review from histology to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

7 January 2021

Uterine carcinosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Collision of endometrioid carcinoma and stromal sarcoma of the uterus: a report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Characteristics of cloned cells of mixed müllerian tumor of the human uterus. Carcinoma cells showing myogenic differentiation in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

The basics of epithelial-mesenchymal transition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

ERBB-2 gene overexpression and amplification in uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

COX-2 expression in uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

The role of surgical cytoreduction in Stage IV endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Uterine sarcomas: analysis of failures with special emphasis on the use of adjuvant radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

The impact of adjuvant radiotherapy on carcinosarcoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

The impact of multi-modal therapy on survival for uterine carcinosarcomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

Differential diagnosis between uterine carcinosarcoma versus carcinoma with sarcomatous metaplasia: an immunohistochemical and ultrastructural case study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.03.041

10.1016/J.YGYNO.2015.03.041

7 January 2021

Identifiers

DOI

1 reference

15 June 2017

1 reference